Fosfomycin I.v. for Treatment of Severely Infected Patients

Inclusion Criteria: * Male or female patients aged ≥ 18 years * Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v. * Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC * Written informed consent of the participant (or person in charge in case of patients incapable of giving consent) Exclusion Criteria: * Previous documentation of the patient in the present study * Patients participating in an interventional clinical trial * Patients with known hypersensitivity to fosfomycin or any of the excipients * Terminally ill patients * Patients with "do not resuscitate order" * Palliative treatment approach * Failure of \> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney * Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS) * Fosfomycin treatment as 4th line treatment or at later stage * Patients with involvement of fungi or mycobacteria in the targeted infection